Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from GENinCode UK Ltd. ( (GB:GENI) ).
GENinCode Plc has announced it will release its audited final results for the year ending December 2024 on June 4, 2025. The company will hold a briefing for equity research analysts and a live investor presentation to discuss the results. This announcement is significant as it reflects GENinCode’s ongoing commitment to transparency and engagement with stakeholders, potentially impacting its market positioning and investor relations.
More about GENinCode UK Ltd.
GENinCode Plc is a UK-based company specializing in genetic risk assessment for cardiovascular disease and ovarian cancer. The company operates in the UK, Europe, and the United States, providing predictive technology that combines clinical algorithms and AI bioinformatics to advance patient risk assessment and preventive care.
Average Trading Volume: 656,102
Technical Sentiment Signal: Sell
Current Market Cap: £4.45M
For detailed information about GENI stock, go to TipRanks’ Stock Analysis page.